Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

PubMed Links for Books (Select 2734682)

1.

Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.

Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW.

J Nucl Med. 2010 Jun;51(6):942-50. doi: 10.2967/jnumed.109.071290. Epub 2010 May 19.

2.

PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.

Niu G, Li Z, Xie J, Le QT, Chen X.

J Nucl Med. 2009 Jul;50(7):1116-23. doi: 10.2967/jnumed.109.061820. Epub 2009 Jun 12.

3.

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG.

J Clin Oncol. 2006 May 20;24(15):2276-82.

4.

Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck.

Schechter NR, Wendt RE 3rd, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, Broemeling LD, Kim EE, Cox JD, Podoloff DA, Ang KK.

J Nucl Med. 2004 Oct;45(10):1683-7.

5.

Preclinical characterisation of 111In-DTPA-trastuzumab.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG.

Br J Pharmacol. 2004 Sep;143(1):99-106. Epub 2004 Aug 2.

6.

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

Gr├╝nwald V, Hidalgo M.

J Natl Cancer Inst. 2003 Jun 18;95(12):851-67. Review.

7.

Targeting peptides and positron emission tomography.

Lundqvist H, Tolmachev V.

Biopolymers. 2002;66(6):381-92. Review.

PMID:
12658725
8.

Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.

Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R 3rd, Oh CS, Hu M, Yu DF, Bryant J, Ang KK, Forster KM, Kim EE, Podoloff DA.

Anticancer Drugs. 2003 Jan;14(1):49-56.

PMID:
12544258
9.

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L.

Cancer Res. 2002 Dec 15;62(24):7350-6.

10.
11.

Biology of HER2 and its importance in breast cancer.

Yarden Y.

Oncology. 2001;61 Suppl 2:1-13. Review.

PMID:
11694782
12.
13.

The basic biology of HER2.

Rubin I, Yarden Y.

Ann Oncol. 2001;12 Suppl 1:S3-8. Review.

PMID:
11521719
14.

Growth factor synthesis and human breast cancer progression.

Ethier SP.

J Natl Cancer Inst. 1995 Jul 5;87(13):964-73. Review.

PMID:
7629883
15.

Predictive value of EGF receptor in breast cancer.

Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U.

Lancet. 1988 Nov 26;2(8622):1258. No abstract available.

PMID:
2903994
16.

Expression of epidermal growth factor receptor in human gastric and colonic carcinomas.

Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E.

Cancer Res. 1988 Jan 1;48(1):137-41.

17.

Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents.

Mendelsohn J.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):889-92. Review.

PMID:
2285602
18.

Epidermal growth factor.

Carpenter G, Cohen S.

J Biol Chem. 1990 May 15;265(14):7709-12. Review. No abstract available.

19.

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM.

Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk